青蒿琥酯联用伯氨喹治疗迁延、复燃疟疾的临床研究

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (1): 98-100.

青蒿琥酯联用伯氨喹治疗迁延、复燃疟疾的临床研究

孙卫华¹, AfelTRAORE²

¹浙江省嘉兴市第一医院医务科,嘉兴 314000,浙江;
²Hospital of Markala, Markala 999053, Mali

收稿日期:2010-12-14 修回日期:2011-01-02 发布日期:2020-09-16
作者简介:孙卫华,男,大学本科,副主任药师,主要从事医院药学研究。Tel: 0573-82080652 E-mail: modibousun93@163.com

Artesunate united Primaquine in the treatment of delay or reconnection malaria

SUN Wei-hua¹,Afel TRAORE²

¹First Hospital of Jiaxing City of Zhejiang Province,Jiaxing 314000,Zhejiang,China;
²Hospital of Markala, Markala 999053, Mali

Received:2010-12-14 Revised:2011-01-02 Published:2020-09-16

摘要/Abstract

摘要： 目的: 探讨青蒿琥酯联用伯氨喹治疗迁延、复燃疟疾的临床疗效。方法: 将82例患者随机分成治疗组和对照组各41例。治疗组:给予青蒿琥酯和伯氨喹:青蒿琥酯首剂 2.4 mg/kg i.v.,12 h 后予 1.2 mg/kg 青蒿琥酯,随后 6 d 每日以 1.2 mg/kg 青蒿琥酯同法给予;同时加服伯氨喹片 22.5 mg q.d.。对照组:给予quinimax,首剂 20 mg/kg,i.v.gtt, 12 h 后予 10 mg/kg,随后每日 12 h 给予 10 mg/kg,直至患者能口服,改口服quinimax片 10 mg/kg,q.8.h,疗程 7 d。结果: 7 d 后治疗组、对照组治愈率分别为 97.5％、95.1％;28 d 治疗组、对照组治愈率分别为 97.5％、90.2％,治疗组与对照组变化相近(P>0.05 );两组的退热时间分别为 28.0、51.6 h,血中疟原虫清除时间分别为 30.4、59.5 h,治疗组较对照组均降低(P<0.01)。结论: 青蒿琥酯联用伯氨喹治疗疟疾作用迅速,副作用小,低复燃率,且对耐奎宁株有效,可作为迁延、复发疟疾以及用奎宁等传统抗疟药治疗失败的首选方法。

关键词: 青蒿琥酯, 伯氨喹, Quinimax, 疟疾

Abstract: AIM: To approach the clinical therapeutic effects of artesunate united Primaquine in the treatment of delay or recrudescence malaria.METHODS: 82 patients were randomly divided into two groups.Patients of the treatment group(n=41)were given an initial dose of 2.4 mg/kg artesunate i.v., 12 h later,a second dose of 1.2 mg/kg artesunate was given in the same way.For the succeeding 6 days,a daily dose of 1.2 mg/kg artesunate was given in the same manner to each patient in the treatment group;and each of the patients were given Primaquine tables 22.5 mg/d, p.o..The control group(n=41)were given an initial dose of 20 mg of quinimax i.v.,12 h later,a second dose of 10 mg/kg quinimax was given in the same way.Thereafter,10 mg/kg of quinimax was given q.12.h.In the same manner until the patients could take medicines by mouth.Quinimax tablets in a dose of 10 mg/kg were then given q.8.h. The course of treatment was 7 d.RESULTS: After 7 and 28 d,the cure rates in the treatment and control group were 97.5％, 95.1％;97.5%,90.2%,respectively.The changes in the treatment and control group were similar(P>0.05). The defervescence time was 28.0 and 51.6 h,and the clearing time of haemoplasmodium was 30.4 and 59.5 h in the treatment and control group,respectively;the differences was significant(P<0.01).CONCLUSION: Artesunate united Primaquine was found to act more quickly in the treatment of pernicious delay or recrudescence malaria,low recurrence rate,with only mild side effects.It is also effective in the treatment of malaria caused by quinine-resistant strains of malaria parasites.It should be the drug of first choice in the treatment of malaria that quinine fails to effect a cure.

Key words: Artesunate, Primaquine, Quinimax, Malaria , , , ,

中图分类号:

R978.61

引用本文

孙卫华, AfelTRAORE. 青蒿琥酯联用伯氨喹治疗迁延、复燃疟疾的临床研究[J]. 中国临床药理学与治疗学, 2011, 16(1): 98-100.

SUN Wei-hua,Afel TRAORE. Artesunate united Primaquine in the treatment of delay or reconnection malaria[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 98-100.

使用本文

0
/ / 推荐

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://manu41.magtech.com.cn/Jweb_clyl/CN/

https://manu41.magtech.com.cn/Jweb_clyl/CN/Y2011/V16/I1/98

参考文献

[1] 郭燕,王俊,陈正堂.青蒿素类药物的药理作用新进展[J].中国临床药理学与治疗学,2006,11(11):615-620.
[2] WHO division of control of tropical disease. Severe and complicated malaria[J].Trans Ray Soc Med Hyg,1990,84(Suppl 2):1-65.
[3] 孙志伟,单承启,李国福,等.复方蒿甲醚和组份之一本芴醇两种剂型治疗恶性疟疾临床对比试验[J].中国临床药理学与治疗学,1999,4(1):21-23.
[4] Pradines B.Antimicrobial agents and chemotherapy[J].Trop Med Parasitol,1999,43(2):418-420.
[5] Krishna S, Woodrow CJ, Staines HM, et al. Reevaluation of how artemisinins work in light of emerging evidence of in vitro resistance[J]. Trends Mol Med,2006,12(5):200-205.
[6] Mantilla G, Oliveros H, Barnston AG. The role of ENSO in understanding changes in Colombia's annual malaria burden by region,1960-2006[J].Malar J,2009,8:6.
[7] 陈新谦,金有豫,汤光.新编药物学[M]. 16版.北京:人民卫生出版社,2007:141-147.

相关文章 14

[1] 廖梦玲, 汪艳, 罗静, 王诺妍, 华玲, 张瑜, 邓非, 袁月, 周军, 周红. 青蒿琥酯抑制巨噬细胞释放前炎症细胞因子的分子作用机制研究[J]. 中国临床药理学与治疗学, 2023, 28(9): 969-978.

[2] 覃晖，赖莉. 青蒿琥酯对体外培养的视网膜神经节细胞氧化应激损伤的保护机制研究[J]. 中国临床药理学与治疗学, 2019, 24(10): 1128-1133.

[3] 董海鹰, 王知非. 青蒿琥酯对人乳腺癌MCF-7血管生成和肿瘤浸润作用研究[J]. 中国临床药理学与治疗学, 2015, 20(5): 537-540.

[4] 阎紫菲, 岑彦艳, 李小丽, 匡梅, 曹冠群, 李攀, 周红. 青蒿琥酯对雨蛙素联合脂多糖致急性胰腺炎模型小鼠的治疗作用[J]. 中国临床药理学与治疗学, 2014, 19(4): 361-365.

[5] 余梦辰, 潘夕春, 李小丽, 李军, 肖康康, 李斌, 周红. 青蒿琥酯增加小鼠腹腔巨噬细胞内化内毒素、大肠埃希菌的作用及可能机制[J]. 中国临床药理学与治疗学, 2012, 17(1): 40-46.

[6] 来丽娜, 任泽恩, 杨柳絮, 张晓一, 王黎敏, 范毅敏. ERK1/2信号通路在青蒿琥酯抑制PDGF-BB诱导HSC细胞增殖中的作用[J]. 中国临床药理学与治疗学, 2011, 16(2): 126-129.

[7] 李天星, 姚朗. 青蒿琥酯对小鼠骨髓造血干祖细胞分化的抑制与毒性作用[J]. 中国临床药理学与治疗学, 2008, 13(12): 1365-1369.

[8] 王宁, 刘鑫, 周红, 曹红卫, 李斌, 鲁永玲, 郑江. 青蒿琥酯对盲肠结扎穿孔术脓毒症小鼠的保护作用[J]. 中国临床药理学与治疗学, 2008, 13(10): 1095-1098.

[9] 张蓉, 李斌, 张乐之, 李军, 丁国富, 和生琦, 罗平, 周红. 青蒿琥酯对热灭活大肠杆菌攻击小鼠的保护作用[J]. 中国临床药理学与治疗学, 2007, 12(2): 156-158.

[10] 郭燕, 王俊, 陈正堂. 青蒿素类药物的药理作用新进展[J]. 中国临床药理学与治疗学, 2006, 11(6): 615-620.

[11] 孔恒, 余清声. 青蒿琥酯对成纤维细胞和内皮细胞的选择性研究[J]. 中国临床药理学与治疗学, 2005, 10(6): 687-690.

[12] 聂蕾, 殷祎隆, 尹少甫. 青蒿琥酯诱导人早幼粒白血病细胞HL60 凋亡的线粒体机制[J]. 中国临床药理学与治疗学, 2005, 10(2): 176-179.

[13] 李哲, 袁守军, 聂丽平, 田增月, 徐兰平, 韩昌明. 青蒿琥酯诱导肿瘤细胞凋亡与抑制存活蛋白表达有关[J]. 中国临床药理学与治疗学, 2004, 9(6): 607-611.

[14] 孙志伟, 单承启, 李国福, 焦岫卿, 刘光裕, 丁德本, 王京燕. 复方蒿甲醚和组份之一本芴醇两种剂型治疗恶性疟疾临床对比试验[J]. 中国临床药理学与治疗学, 1999, 4(1): 21-24.

编辑推荐

Metrics

阅读次数

全文

摘要

本文评价

摘要

参考文献

相关文章

编辑推荐

Metrics

本文评价

回顶部